Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment

Kevin L Winthrop, Jeffrey R Curtis, Kunihiro Yamaoka, Eun Bong Lee, Tomohiro Hirose, Jose L Rivas, Kenneth Kwok, Gerd R Burmester, Kevin L Winthrop, Jeffrey R Curtis, Kunihiro Yamaoka, Eun Bong Lee, Tomohiro Hirose, Jose L Rivas, Kenneth Kwok, Gerd R Burmester

Abstract

Introduction: Risk of herpes zoster (HZ) is increased with Janus kinase inhibitor use. We evaluated clinical study data relating to HZ management in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) receiving tofacitinib.

Methods: This post hoc analysis included data from 21 RA and 3 PsA clinical studies; data were pooled for tofacitinib doses. Outcomes of HZ events (serious and non-serious) and tofacitinib treatment changes were evaluated in response to first and second HZ events. Median time to resolution was stratified by dermatomal involvement, history of HZ prior to tofacitinib, changes to tofacitinib treatment, anti-viral and corticosteroid use, and tofacitinib dose.

Results: Seven hundred eighty-three (11.1%, N = 7061) patients with RA experienced ≥ 1 HZ event, 63 (8.0%) of whom had ≥ 2 HZ events. In patients with PsA, 36 (4.6%, N = 783) experienced ≥ 1 HZ event, 1 (2.8%) of whom had ≥ 2 HZ events. For most HZ events, tofacitinib treatment was unchanged or temporarily discontinued. The majority of patients received anti-viral treatment, most within 3 days of onset. Post-herpetic neuralgia developed in 6.9% and 3.2% of patients with RA with first and second events, respectively, and in 2.8% of patients with PsA with a first event. Most first and second events resolved (RA: 97.6% and 96.8%, respectively; PsA: 94.4% and 100%, respectively). Median time to resolution was 22.0 days for first and 15.0 days for second events for RA and 20.5 days for first and 11.0 days for second events (n = 1) for PsA. Time to resolution of first events for RA and PsA was generally numerically shorter for patients with single dermatomal HZ, history of HZ, or anti-viral use versus those without.

Conclusion: Among patients receiving tofacitinib, recurrent events were more common in patients with RA versus PsA; HZ duration was shorter for repeat events.

Trial registration: NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT00413699, NCT00661661, NCT01877668, NCT01882439, NCT01976364.

Keywords: Anti-viral; Clinical management; Herpes zoster; Infections; Psoriatic arthritis; Rheumatoid arthritis; Tofacitinib.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Kaplan-Meier plot of time to second HZ event following the first HZ event in patients with RA receiving tofacitinib. Kaplan-Meier estimates of the second HZ event are presented from the end of the first HZ event to the occurrence of the second HZ event. Patients whose first HZ end date occurred either after the date of onset of the second HZ event, or after the last dose of tofacitinib with no second HZ event, were excluded from this analysis. The last second HZ event occurred at ~ month 78, with 13 patients remaining at risk beyond this point. The final month of observation was month 122. HZ herpes zoster, RA rheumatoid arthritis
Fig. 2
Fig. 2
Responses to HZ in patients with RA receiving tofacitinib: a changes to tofacitinib treatment due to first HZ event, stratified by event severity, and b anti-viral use due to first HZ event, stratified by event severity. One patient with unknown HZ severity had unknown action and received no anti-viral therapy; this patient is included in the overall values presented. HZ herpes zoster, N number of patients with first HZ event, RA rheumatoid arthritis
Fig. 3
Fig. 3
Time to resolutiona of a first HZ event and b second HZ event in patients with RA, stratified by dermatome involvement, history of HZb, changes to tofacitinib treatment, anti-viral use, corticosteroid usec, and average tofacitinib dose. aTime to resolution in patients with both a date of onset and date of resolution for the HZ event. bMedical history of HZ prior to the first dose of tofacitinib. cCorticosteroid use within 14 days prior to the HZ event. BID twice daily, HZ herpes zoster, N number of patients with non-missing data, Q1 first quartile (25th percentile), Q3 third quartile (75th percentile), RA rheumatoid arthritis
Fig. 4
Fig. 4
Responses to HZ in patients with PsA receiving tofacitinib: a changes to tofacitinib treatment for first HZ event; b time to resolutiona of first HZ event, stratified by dermatome involvement, history of HZb, changes to tofacitinib treatment, anti-viral use, corticosteroid usec, and average tofacitinib dose. aTime to resolution in patients with both a date of onset and date of resolution for the HZ event. bMedical history of HZ prior to the first dose of tofacitinib. cCorticosteroid use within 14 days prior to the HZ event. BID twice daily, HZ herpes zoster, N number of patients with non-missing data, PsA psoriatic arthritis, Q1 first quartile (25th percentile), Q3 third quartile (75th percentile)

References

    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
    1. Nagel MA, Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol. 2014;27:356–360.
    1. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in auto-immune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–2337.
    1. Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofw205.
    1. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019;58:i34–i42.
    1. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–2684.
    1. Burmester GR, Curtis JR, Yun H, et al. An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data. Drug Saf. 2020;43:379–392.
    1. Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302–309.
    1. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–1550.
    1. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–1536.
    1. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395.
    1. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960–1968.
    1. Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79:1290–1297.
    1. Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80:304–311.
    1. Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache? Drugs. 2020;80:1183–1201.
    1. Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb/IV randomized study. Arthritis Care Res (Hoboken) 2020;72:353–359.
    1. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318–328.
    1. Kato M. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med. 2020;43:72–78.
    1. Bing N, Zhou H, Chen X, et al. Contribution of a European-prevalent variant near CD83 and an East Asian-prevalent variant near IL17RB to herpes zoster risk in tofacitinib treatment: results of genome-wide association study meta-analyses. Arthritis Rheumatol. 2021;73:1155–1166.
    1. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755–1766.
    1. Cohen S, van Vollenhoven R, Winthrop K, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT Phase 3 clinical program [abstract]. Arthritis Rheumatol. 2019;71(Suppl 10).
    1. Winthrop KL, Takeuchi T, Burmester G, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Arthritis Rheumatol. 2020;72 (Suppl 10).
    1. Cohen SB, Van Vollenhoven R, Curtis JR, et al. THU0197 Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [abstract] Ann Rheum Dis. 2020;79(Suppl 1):319–320.
    1. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–1847.
    1. Qian J, Macartney K, Heywood AE, Sheridan S, Liu B. Risk of recurrent herpes zoster in a population-based cohort study of older adults. J Am Acad Dermatol. 2021;85:611–618.
    1. Kaine J, Tesser J, Takiya L, et al. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2020;39:2127–2137.
    1. US Food and Drug Administration. Xeljanz® (tofacitinib): highlights of prescribing information. 2019. . Accessed 2 Nov 2021.
    1. US Food and Drug Administration. OLUMIANT (baricitinib): highlights of prescribing information. 2018. . Accessed 2 Nov 2021.
    1. US Food and Drug Administration. RINVOQ™ (upadacitinib): highlights of prescribing information. 2019. . Accessed 2 Nov 2021.
    1. Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017;31:20–29.
    1. Cates M, Donati M, Gillet S, Ustianowski A, Galloway J. Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology (Oxford) 2018;57:596–605.
    1. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125–132.
    1. Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys. 2017;96:656–663.
    1. Nakamura Y, Miyagawa F, Okazaki A, et al. Clinical and immunologic features of recurrent herpes zoster (HZ) J Am Acad Dermatol. 2016;75:950–6.e1.
    1. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2008;57:1–30.
    1. US Food and Drug Administration. ZOSTAVAX® (zoster vaccine live): highlights of prescribing information. 2019. . Accessed 2 Nov 2021.
    1. US Food and Drug Administration. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for intramuscular injection, highlights of prescribing information. 2017. . Accessed 2 Nov 2021.
    1. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged >/=60 years. J Infect Dis. 2016;213:1872–1875.
    1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284.
    1. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
    1. Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67:616–625.
    1. Kremer JM, Kivitz AJ, Simon-Campos JA, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015;17:95.
    1. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–1905.
    1. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–981.
    1. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–629.
    1. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH. Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–1158.
    1. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514–521.
    1. Conaghan PG, Østergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75:1024–1033.
    1. Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311–1316.
    1. McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124–131.
    1. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687–695.
    1. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969–1977.
    1. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460.
    1. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
    1. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
    1. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–261.
    1. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
    1. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
    1. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.
    1. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.
    1. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.
    1. Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:E270–E283.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere